[go: up one dir, main page]

CY1120996T1 - Αντισωματα anti-angptl3 και χρησεις αυτων - Google Patents

Αντισωματα anti-angptl3 και χρησεις αυτων

Info

Publication number
CY1120996T1
CY1120996T1 CY181101324T CY181101324T CY1120996T1 CY 1120996 T1 CY1120996 T1 CY 1120996T1 CY 181101324 T CY181101324 T CY 181101324T CY 181101324 T CY181101324 T CY 181101324T CY 1120996 T1 CY1120996 T1 CY 1120996T1
Authority
CY
Cyprus
Prior art keywords
diseases
disorders
hangptl3
inhibits
treatment
Prior art date
Application number
CY181101324T
Other languages
English (en)
Inventor
Mark W Sleeman
Viktoria Gusarova
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120996(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CY1120996T1 publication Critical patent/CY1120996T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Παρέχεται ένα πλήρως ανθρώπινο αντίσωμα ή αντιγονοδεσμευτικό θραύσμα ενός ανθρώπινου αντισώματος που δεσμεύει ειδικά και αναστέλλει ή παρεμποδίζει τουλάχιστον μία δράση της ανθρώπινης ομοιάζουσας με αγγειοποιητίνη πρωτεΐνης 3 (hANGPTL3). Τα ανθρώπινα αντισώματα αντι-hANGPTL3 είναι χρήσιμα στη θεραπεία νόσων ή διαταραχών που σχετίζονται με την ANGPTL3, όπως υπερλιπιδαιμία, υπερλιποπρωτεϊναιμία και δυσλιπιδαιμία, συμπεριλαμβανομένης της υπερτριγλυκεριδαιμίας, της υπερχοληστερολαιμίας, της χυλομικροναιμίας και ούτω καθεξής. Επιπλέον, τα αντισώματα αντι-hANGPTL3 μπορούν να χορηγηθούν σε ένα υποκείμενο που τα έχει ανάγκη για την πρόληψη ή τη θεραπεία νόσων ή διαταραχών για τις οποίες ο μη φυσιολογικός μεταβολισμός των λιπιδίων αποτελεί παράγοντα κινδύνου. Τέτοιες νόσοι ή διαταραχές συμπεριλαμβάνουν τις καρδιαγγειακές παθήσεις, όπως αθηροσκλήρωση και νόσους της στεφανιαίας αρτηρίας• την οξεία παγκρεατίτιδα• τη μη αλκοολική στεατοηπατίτιδα (NASH)• τον διαβήτη• την παχυσαρκία• και τα παρόμοια.
CY181101324T 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων CY1120996T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498518P 2011-06-17 2011-06-17
US201161578309P 2011-12-21 2011-12-21
PCT/US2012/042338 WO2012174178A1 (en) 2011-06-17 2012-06-14 Anti-angptl3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CY1120996T1 true CY1120996T1 (el) 2019-12-11

Family

ID=46298728

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101324T CY1120996T1 (el) 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων
CY2021036C CY2021036I2 (el) 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2021036C CY2021036I2 (el) 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων

Country Status (46)

Country Link
US (7) US9018356B2 (el)
EP (2) EP2721065B1 (el)
JP (2) JP6400471B2 (el)
KR (1) KR102031007B1 (el)
CN (1) CN103732624B (el)
AR (1) AR087329A1 (el)
AU (1) AU2012271663B2 (el)
CA (1) CA2838867C (el)
CL (1) CL2013003552A1 (el)
CO (1) CO6821892A2 (el)
CR (1) CR20130621A (el)
CY (2) CY1120996T1 (el)
DK (1) DK2721065T3 (el)
DO (1) DOP2013000299A (el)
EC (1) ECSP13013085A (el)
ES (1) ES2699499T3 (el)
FI (1) FIC20210028I1 (el)
FR (1) FR21C1061I2 (el)
GT (1) GT201300306A (el)
HR (1) HRP20182098T1 (el)
HU (1) HUS2100034I1 (el)
IL (2) IL229612B (el)
JO (1) JO3412B1 (el)
LT (2) LT2721065T (el)
LU (1) LUC00231I2 (el)
MA (1) MA35190B1 (el)
MX (2) MX337644B (el)
MY (1) MY160516A (el)
NI (1) NI201300136A (el)
NL (1) NL301122I2 (el)
NO (2) NO2021037I1 (el)
PE (1) PE20141166A1 (el)
PH (1) PH12013502570B1 (el)
PL (1) PL2721065T3 (el)
PT (1) PT2721065T (el)
RS (1) RS58310B1 (el)
RU (1) RU2620064C2 (el)
SG (1) SG195165A1 (el)
SI (1) SI2721065T1 (el)
SM (1) SMT201800658T1 (el)
TR (1) TR201816591T4 (el)
TW (3) TWI644922B (el)
UA (1) UA114891C2 (el)
UY (2) UY39340A (el)
WO (1) WO2012174178A1 (el)
ZA (1) ZA201308879B (el)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
PT3416684T (pt) * 2016-02-17 2023-07-04 Regeneron Pharma Métodos para tratamento ou prevenção da aterosclerose por administração de um inibidor da angptl3
CN109069868B (zh) * 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
AU2017248356A1 (en) * 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor
JP7201437B2 (ja) * 2016-04-28 2023-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 家族性高コレステロール血症を有する患者を処置するための方法
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP7133551B2 (ja) 2016-11-17 2022-09-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法
EP3967765A1 (en) 2017-07-06 2022-03-16 FrieslandCampina Nederland B.V. Cell culture process for making a glycoprotein
US11977081B2 (en) 2017-12-18 2024-05-07 Regeneron Pharmaceuticals, Inc. ANGPTL8 assay and uses thereof
WO2019126123A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
AU2019215363A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20200127979A (ko) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
EP4317959A3 (en) 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
BR112020026348A2 (pt) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
US20220025344A1 (en) * 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
KR20210114927A (ko) 2019-01-16 2021-09-24 리제너론 파마슈티칼스 인코포레이티드 이황화 결합을 특징 짓는 방법
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
MX2021013519A (es) 2019-05-13 2021-12-10 Regeneron Pharma Ensayos de union de ligandos competitivos mejorados.
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
WO2021001804A1 (en) * 2019-07-04 2021-01-07 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
CN114667450B (zh) 2019-09-24 2025-05-02 里珍纳龙药品有限公司 用于色谱介质的使用和再生的系统及方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
EP4354145B1 (en) 2020-01-21 2025-09-17 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
KR20220131935A (ko) 2020-01-22 2022-09-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항angptl3 항체 및 이의 용도
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
KR20230113280A (ko) 2020-11-25 2023-07-28 리제너론 파마슈티칼스 인코포레이티드 비수성 멤브레인 유화법을 사용한 지속 방출 제형
CN116710124A (zh) 2020-12-17 2023-09-05 瑞泽恩制药公司 包封蛋白质的微凝胶的制造
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
MX2023010794A (es) 2021-03-26 2023-10-25 Regeneron Pharma Metodos y sistemas para el desarrollo de protocolos de mezcla.
WO2022205021A1 (zh) * 2021-03-30 2022-10-06 复旦大学附属儿科医院 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
US20240352113A1 (en) * 2021-07-21 2024-10-24 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
JP2024531800A (ja) 2021-09-20 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体の不均一性を制御する方法
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
CA3236367A1 (en) 2021-10-26 2023-05-04 Michelle Lafond Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
WO2023122656A1 (en) * 2021-12-22 2023-06-29 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors
JP2025508233A (ja) 2022-03-18 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ポリペプチド変異体を分析するための方法およびシステム
EP4518969A1 (en) 2022-05-02 2025-03-12 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白
CN116143919B (zh) * 2022-11-01 2025-06-13 中国药科大学 全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024130165A1 (en) * 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
WO2025096932A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
ATE357216T1 (de) 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
KR101012904B1 (ko) 2001-11-16 2011-02-08 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는조성물 및 이를 사용하는 방법
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
NZ568739A (en) 2005-12-16 2010-09-30 Regeneron Pharma Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
CN101522716B (zh) * 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
HUE033960T2 (en) 2006-12-08 2018-01-29 Lexicon Pharmaceuticals Inc Monoclonal Antibodies to ANGPTL3
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
ES2677969T3 (es) 2010-01-08 2018-08-07 Ionis Pharmaceuticals, Inc. Modulación de la expresión tipo angiopoyetina 3
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
KR102232287B1 (ko) * 2011-06-21 2021-03-29 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
WO2015100394A1 (en) 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP3845547A1 (en) 2014-05-01 2021-07-07 Ionis Pharmaceuticals, Inc. Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression
CA2955294A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
PT3416684T (pt) 2016-02-17 2023-07-04 Regeneron Pharma Métodos para tratamento ou prevenção da aterosclerose por administração de um inibidor da angptl3
CN109069868B (zh) 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
AU2017248356A1 (en) 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor
JP7201437B2 (ja) 2016-04-28 2023-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 家族性高コレステロール血症を有する患者を処置するための方法
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies

Also Published As

Publication number Publication date
US20250136675A1 (en) 2025-05-01
PH12013502570A1 (en) 2014-01-27
TW201815822A (zh) 2018-05-01
US20150197564A1 (en) 2015-07-16
US20130171149A1 (en) 2013-07-04
ECSP13013085A (es) 2014-01-31
UY34137A (es) 2013-01-03
WO2012174178A1 (en) 2012-12-20
PT2721065T (pt) 2018-12-06
US9018356B2 (en) 2015-04-28
MX361859B (es) 2018-12-18
EP2721065B1 (en) 2018-09-12
RS58310B1 (sr) 2019-03-29
FR21C1061I1 (fr) 2022-01-21
JP2018166516A (ja) 2018-11-01
TWI644922B (zh) 2018-12-21
MX337644B (es) 2016-03-14
EP2721065A1 (en) 2014-04-23
LT2721065T (lt) 2018-12-10
DK2721065T3 (en) 2018-12-03
SMT201800658T1 (it) 2019-01-11
IL229612B (en) 2019-06-30
SG195165A1 (en) 2013-12-30
MX2013014345A (es) 2014-01-31
FIC20210028I1 (fi) 2021-09-09
PH12013502570B1 (en) 2019-01-16
LUC00231I2 (el) 2025-02-03
CY2021036I2 (el) 2022-05-27
RU2013155906A (ru) 2015-07-27
PE20141166A1 (es) 2014-09-16
LTC2721065I2 (el) 2022-10-25
CO6821892A2 (es) 2013-12-31
ES2699499T3 (es) 2019-02-11
ZA201308879B (en) 2014-07-30
GT201300306A (es) 2015-03-09
FR21C1061I2 (fr) 2022-11-18
TW201313738A (zh) 2013-04-01
US9951127B2 (en) 2018-04-24
JP6400471B2 (ja) 2018-10-03
CA2838867C (en) 2020-07-14
NO2025028I1 (no) 2025-06-13
AU2012271663B2 (en) 2017-04-20
RU2620064C2 (ru) 2017-05-22
CY2021036I1 (el) 2022-03-24
LTPA2021009I1 (el) 2021-09-27
CR20130621A (es) 2014-02-12
NZ619092A (en) 2016-03-31
KR102031007B1 (ko) 2019-11-08
EP3418301A1 (en) 2018-12-26
UA114891C2 (uk) 2017-08-28
US10358487B2 (en) 2019-07-23
MA35190B1 (fr) 2014-06-02
CL2013003552A1 (es) 2014-07-25
MY160516A (en) 2017-03-15
JO3412B1 (ar) 2019-10-20
DOP2013000299A (es) 2014-04-15
TR201816591T4 (tr) 2018-11-21
US20190315851A1 (en) 2019-10-17
HRP20182098T1 (hr) 2019-02-08
PL2721065T3 (pl) 2019-02-28
SI2721065T1 (sl) 2018-12-31
NL301122I2 (nl) 2021-12-30
NO2021037I1 (no) 2021-09-15
AU2012271663A1 (en) 2014-01-16
NL301122I1 (el) 2021-09-01
UY39340A (es) 2021-08-31
CA2838867A1 (en) 2012-12-20
IL229612A0 (en) 2014-01-30
AR087329A1 (es) 2014-03-19
US20220403016A1 (en) 2022-12-22
US20220153825A1 (en) 2022-05-19
US20190092845A1 (en) 2019-03-28
IL259436A (en) 2018-07-31
NI201300136A (es) 2014-05-15
CN103732624A (zh) 2014-04-16
HUS2100034I1 (hu) 2021-10-28
KR20140037218A (ko) 2014-03-26
TW201920261A (zh) 2019-06-01
JP2014523739A (ja) 2014-09-18
CN103732624B (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
CY1120996T1 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
CY1118898T1 (el) Ανθρωπινα αντισωματα για πρωτεϊνη 4 τυπου ανθρωπινης αγγειοποιητινης
CY1124902T1 (el) Μεθοδοι αντιμετωπισης της υπερλιπιδημιας με αναστολεα angptl8 και αναστολεα angptl3
EA201500064A1 (ru) Активаторы ampk и их применение в терапевтических целях
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
EP2740489A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
CR20130624A (es) Proteínas de unión a antígeno
BRPI0911520A2 (pt) novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de angiogênese.
EP2911754A4 (en) MEDICAL LEG ARRANGEMENT FOR INCREASING THE MOVEMENT AREA OF A LEG TO SUPPORT HEALING AND TO STRENGTHEN DAMAGED, INJURED AND / OR REPLACED BONES, MUSCLES AND / OR WOVEN LEGS
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
CY1118254T1 (el) Αντισωματα toy βμρ-6
BR112014029219A8 (pt) moléculas de ligação de il-6
CY1112887T1 (el) Παραγωγα 4-κυκλοαλκυλ-υποκατεστημενης τετραϋδροκινολινης και η χρηση τους ως φαρμακα
CY1121707T1 (el) Αναστολεας πρωτεϊνης μεταφορας εστερων χοληστερολης (cetp) και φαρμακευτικες συνθεσεις που περιλαμβανουν τον εν λογω αναστολεα για χρηση στη θεραπεια ή την προληψη καρδιαγγειακων νοσηματων
PL2341900T3 (pl) Produkt medyczny i leczenie
BR112013020913A2 (pt) tratamento de doença de crohn fistulizante
BR112017001146A2 (pt) terapia com anticorpo anti-vegfr2 para carcinoma hepatocelular
EP2506864A4 (en) TREATMENT AND PROPHYLAXIS OF CANCER DISORDERS ASSOCIATED WITH INTRA-CELLULAR ONCOPROTEINS BY ANTIBODY THERAPY OR VACCINATION
EA200900923A1 (ru) Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний
TN2013000490A1 (en) Anti-angptl3 antibodies and uses thereof
PH12012501279A1 (en) Human antibodies to human angiopoietin-like protein 4
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
CY1113915T1 (el) Θεραπεια ρευματοειδους ασθενειας με καθυστερημενης-απελευθερωσης γλυκοκορτικοειδες